



## (51) International Patent Classification:

*A61K 39/00* (2006.01) *C07K 14/00* (2006.01)*A61P 35/00* (2006.01)

## (21) International Application Number:

PCT/EP2021/064415

## (22) International Filing Date:

28 May 2021 (28.05.2021)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

20177183.9 28 May 2020 (28.05.2020) EP

(71) Applicant: **HUBRO THERAPEUTICS AS** [NO/NO];  
Ullernchausséen 64, 0379 Oslo (NO).(72) Inventors: **ERIKSEN, Henrik**; c/o Hubro Therapeutics  
AS Ullernchausséen 64, 0379 Oslo (NO). **ERIKSEN, Jon  
Amund**; c/o Hubro Therapeutics AS Ullernchausséen 64,  
0379 Oslo (NO).(74) Agent: **ARENDS, William Gerrit**; Marks & Clerk LLP 15  
Fetter Lane, London EC4A 1BW (GB).(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

## Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

## (54) Title: A PEPTIDE COCKTAIL




FIG. 16

(57) **Abstract:** There is disclosed a peptide capable of inducing an immune response against: a ASTE1 -1a frameshift mutant protein, wherein the peptide comprises at least 10 consecutive amino acids of SEQ ID NO: 26; a TAE1 $\beta$  -1a frameshift mutant protein, wherein the peptide comprises at least 10 consecutive amino acids of SEQ ID NO: 27; a KIAA2018 -1a frameshift mutant protein, wherein the peptide comprises an immunogenic fragment of one of SEQ ID NOs: 9-12, wherein the fragment comprises at least 8 consecutive amino acids of one of one of SEQ ID NOs: 9-12; or a SLC22A9 -1a frameshift mutant protein, wherein the peptide comprises at least 8 consecutive amino acids of one of SEQ ID NOs: 14-18. There is also disclosed a peptide mixture comprising a first and second peptide, each independently selected from one of the peptides described above and a peptide capable of inducing an immune response against a T $\alpha$ E $\beta$ E2 -1a frameshift mutant protein.